[1]黄媚媚.对比使用沙库巴曲缬沙坦与缬沙坦治疗顽固性心力衰竭的临床研究[J].大众科技,2021,23(5):75-77.
　Clinical Study on the Treatment of Refractory Heart Failure by Comparing the Use of Sacubatril Valsartan and Valsartan[J].Popular Science & Technology,2021,23(5):75-77.
点击复制

对比使用沙库巴曲缬沙坦与缬沙坦治疗顽固性心力衰竭的临床研究()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
23
期数:
2021年5
页码:
75-77
栏目:
医药与卫生
出版日期:
2021-05-20

文章信息/Info

Title:
Clinical Study on the Treatment of Refractory Heart Failure by Comparing the Use of Sacubatril Valsartan and Valsartan
作者:
黄媚媚
（广西玉林市博白县人民医院，广西 博白 537600）
关键词:
顽固性心力衰竭; 沙库巴曲缬沙坦; 缬沙坦
Keywords:
refractory heart failure sacubitril valsartan valsartan
文献标志码:
A
摘要:
目的：对比观察沙库巴曲缬沙坦与缬沙坦在治疗顽固性心力衰竭中的疗效及预后是否存在差别。方法：本研究纳入124例顽固性心衰患者，按照1∶1比例将患者随机分为沙库巴曲缬沙坦组与缬沙坦组。分别在常规抗心衰治疗基础上加用沙库巴曲缬沙坦或缬沙坦。观察比较两组患者的心率、收缩压、心脏彩超、心功能分级、血红蛋白、红细胞压积、肌酐、血脂、电解质、脑钠肽前体、6分钟步行实验（6MWT）、预后情况。结果：两个治疗组在治疗后，对血红蛋白、前白蛋白、红细胞压积、血肌酐、总胆固醇、甘油三酯、钠离子、钾离子的影响无明显差异，但是沙库巴曲缬沙坦对脑钠肽前体、6MWT以及心脏彩超各参数（LVEF、LAD、LVEDD、RA、RV）的改善明显优于缬沙坦，提示沙库巴曲缬沙坦治疗顽固性心衰疗效明显优于缬沙坦，差异有统计学意义（P＜0.05）。结论：在治疗顽固性心衰中，沙库巴曲缬沙坦疗效优于缬沙坦，并能更好地改善顽固性心衰患者预后。
Abstract:
Objective: To compare the efficacy and prognosis of sacubitril and valsartan in the treatment of refractory heart failure. Methods: In this study, 124 patients with refractory heart failure were enrolled. The patients were randomly divided into sacubitril valsartan group and valsartan group according to a ratio of 1:1. Sacubitril valsartan or valsartan was added respectively on the basis of conventional anti-heart failure treatment. The heart rate, systolic blood pressure, cardiac color Doppler ultrasound, cardiac function classification, hemoglobin, hematocrit, creatinine, blood lipids, electrolytes, pro-brain natriuretic peptide, 6-minute walk test (6MWT), and prognosis of the two groups of patients were observed and compared. Results: After treatment, the two treatment groups had no significant differences in the effects of hemoglobin, prealbumin, hematocrit, serum creatinine, total cholesterol, triglycerides, sodium ions, and potassium ions. However, the effects of sacubitril valsartan on the pro-brain natriuretic peptide, 6MWT, and cardiac color Doppler ultrasound parameters (LVEF, LAD, LVEDD, RA, RV) was significantly better than valsartan, suggesting that sacubitril valsartan are significantly advance than valsartan in the treatment of refractory heart failure, the difference was statistically significant (P<0.05). Conclusion: In the treatment of refractory heart failure, sacubitril valsartan are more effective than valsartan, and can better improve the prognosis of patients with refractory heart failure.

参考文献/References:

[1]　Rogers C, Bush N. Heart failure: Pathophysiology, diagnosis, medical treatment guidelines, and nursing management[J]. The Nursing Clinics of North America, 2015, 50(4): 787-799. [2]　Baman J R, Ahmad F S. Heart failure[J]. Jama, 2020, 324(10): 1015. [3]　武剑华. 内科治疗难治性心力衰竭的研究进展[J]. 中国社区医师，2018，34(32): 5，7. [4] Finnegan P M, Gleason B L. Combination ACE inhibitors and angiotensin II receptor blockers for hypertension[J]. The Annals of Pharmacotherapy, 2003, 37(6): 886-889. [5] 段骁睿，李广平. 沙库巴曲缬沙坦抑制心脏重构的研究进展[J]. 天津医药，2020，48(12): 1240-1243. [6] 王华，梁延春. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志，2018，46(10): 760-789. [7] 慢性心力衰竭基层诊疗指南(2019年)[J]. 中华全科医师杂志，2019(10): 936-947. [8] Thai H, Raya T. Angiotensin II receptor blockers[J]. Coronary Artery Disease, 1999, 10(6):377-381. [9] 刘晨阳，唐碧，康品方. 沙库巴曲缬沙坦在心力衰竭药物治疗中的研究进展[J]. 齐齐哈尔医学院学报，2020，41(17): 2206-2208. [10] Kober L, Torp-Pedersen C. Valsartan: the past, present and future[J]. Future Cardiology, 2005, 1(5): 591-598. [11] Scardovi A B, Boccanelli A. Valsartan/sacubitril in heart failure and hypotension: how, when and why[J]. European Heart Journal Supplements: Journal of the European Society of Cardiology, 2019, 21(Suppl B): B88. [12] Das B B, Scholl F, Vandale B, et al. Sacubitril/valsartan: potential treatment for paediatric heart failure[J]. Cardiology in the Young, 2018, 28(9): 1077-1081. [13] Senni M, McMurray J J, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens[J]. European Journal of Heart Failure, 2016, 18(9): 1193-1202. [14] Heyse A, Manhaeghe L, Mahieu E, et al. Sacubitril/valsartan in heart failure and end-stage renal insufficiency[J]. ESC Heart Failure, 2019, 6(6): 1331-1333.

备注/Memo

备注/Memo:
【收稿日期】2021-03-08 【作者简介】黄媚媚（1985－），女，广西玉林人，广西玉林市博白县人民医院主治医师，从事心血管内科临床工作。
更新日期/Last Update: 2021-09-07